Nooms body scanner helps you track not just weight but also your body fat percentage and muscle mass
Customisation, balance and value-for-money based on smaller appetites will be key to relevance
But for many Americans, the cost has made them out of reach
Esposito G, Dottori L, Pivetta G, et al
It was discovered in 2012,[3] by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide.[4] Clinical trials were started in 2015, and phase 3 was completed in 2016.[5] Researchers at the University of Leeds and Novo Nordisk reported in 2017 that it can also be used for the treatment of obesity.[6] It reduces hunger, food craving and body fat.[7] FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour.[8] On December 5, 2017, semaglutide was approved by the US FDA